Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Apple
AAPL
|
+$953M |
| 2 |
NVIDIA
NVDA
|
+$784M |
| 3 |
Meta Platforms (Facebook)
META
|
+$753M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$316M |
| 5 |
Chipotle Mexican Grill
CMG
|
+$315M |
Top Sells
| 1 |
Amazon
AMZN
|
+$1.17B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$506M |
| 4 |
Abbott
ABT
|
+$388M |
| 5 |
Johnson & Johnson
JNJ
|
+$325M |
Sector Composition
| 1 | Technology | 20.29% |
| 2 | Healthcare | 16.94% |
| 3 | Consumer Discretionary | 12.83% |
| 4 | Consumer Staples | 9.16% |
| 5 | Industrials | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
UCL
3376
uCloudlink Group
UCL
$96.7M
| $145K | ﹤0.01% |
57,205
+11,800
| +26% | +$29.9K |
|
|
SYRS
3377
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $145K | ﹤0.01% |
46,135
+300
| +0.7% | +$943 |
|
3378
Alset
AEI
$146M
| $144K | ﹤0.01% |
93,066
+1,600
| +2% | +$2.48K |
|
3379
Sonnet BioTherapeutics
SONN
$27M
| $144K | ﹤0.01% |
1,670
+1,578
| +1,715% | +$136K |
|
3380
Elutia
ELUT
$55.5M
| $143K | ﹤0.01% |
60,416
+38,500
| +176% | +$91.1K |
|
3381
Phathom Pharmaceuticals
PHAT
$856M
| $143K | ﹤0.01% |
+10,000
| New | +$143K |
|
|
CLVR
3382
DELISTED
Clever Leaves Holdings Inc. Common Shares
CLVR
| $143K | ﹤0.01% |
23,588
+4,065
| +21% | +$24.6K |
|
3383
Korro Bio
KRRO
$323M
| $142K | ﹤0.01% |
8,184
+454
| +6% | +$7.88K |
|
3384
Key Tronic
KTCC
$36.7M
| $142K | ﹤0.01% |
25,060
-2,440
| -9% | -$13.8K |
|
3385
Research Solutions
RSSS
$107M
| $142K | ﹤0.01% |
69,400
-10,018
| -13% | -$20.5K |
|
|
HLTH
3386
DELISTED
Cue Health Inc. Common Stock
HLTH
| $142K | ﹤0.01% |
384,900
+177,800
| +86% | +$65.6K |
|
|
GTH
3387
DELISTED
Genetron Holdings Limited ADS
GTH
| $142K | ﹤0.01% |
50,833
-2,134
| -4% | -$5.96K |
|
|
EZGO
3388
EZGO Technologies
EZGO
$758K
| $141K | ﹤0.01% |
2,145
+787
| +58% | +$51.7K |
|
|
ETHZ
3389
ETHZilla Corporation Common Stock
ETHZ
$399M
| $140K | ﹤0.01% |
6,316
+277
| +5% | +$6.14K |
|
3390
CareCloud
CCLD
$160M
| $140K | ﹤0.01% |
47,600
+7,300
| +18% | +$21.5K |
|
|
HEPA
3391
DELISTED
Hepion Pharmaceuticals
HEPA
| $140K | ﹤0.01% |
267
-17
| -6% | -$8.91K |
|
3392
Hecla Mining
HL
$7.47B
| $140K | ﹤0.01% |
+27,200
| New | +$140K |
|
3393
Magyar Bancorp
MGYR
$111M
| $139K | ﹤0.01% |
13,400
-2,089
| -13% | -$21.7K |
|
|
SIEN
3394
DELISTED
Sientra, Inc.
SIEN
| $139K | ﹤0.01% |
47,270
+19,700
| +71% | +$57.9K |
|
3395
2x Long VIX Futures ETF
UVIX
$426M
| $137K | ﹤0.01% |
+307
| New | +$137K |
|
|
SNCE
3396
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $137K | ﹤0.01% |
32,265
+13,161
| +69% | +$55.9K |
|
3397
Abeona Therapeutics
ABEO
$346M
| $135K | ﹤0.01% |
33,537
-3,300
| -9% | -$13.3K |
|
3398
CervoMed
CRVO
$80.1M
| $135K | ﹤0.01% |
26,873
+800
| +3% | +$4.02K |
|
3399
Gray Media, Inc. Class A
GTN.A
$1.02B
| $135K | ﹤0.01% |
14,900
-200
| -1% | -$1.81K |
|
3400
IO Biotech
IOBT
$126M
| $135K | ﹤0.01% |
69,100
+7,400
| +12% | +$14.5K |
|